EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study)
https://doi.org/10.14412/1995-4484-2013-639-45
Abstract
Objective. To evaluate the effectiveness and tolerance of Etanercept (ETN) therapy in patients with rheumatoid arthritis (RA).
Material and Methods. 188 adult patients with severe and moderate RA (average DAS28 score of 6.26±0.89) subcutaneously received 50 mg/wk ETC during 24 wk along with therapy using disease-modifying antirheumatic drugs (DMARDs). The effectiveness was assessed using the EULAR and ACR20/50/70 criteria, dynamics of HAQ, SDAI, CDAI, ESR, and the C-reactive protein level.
Results. By the end of the study, low activity of the disease according to EULAR (DAS28 score ≤ 3.2) was achieved in 31.9% of patients; remission (DAS28 score ≤ 2.6) was achieved in 17% of patients. ACR20/50/70 response was achieved in 72.3; 47.8 and 20.2% of patients, respectively. A decrease in the HAQ index by at least 0.25 points was achieved in 67.5% of patients. The overall EULAR response (moderate and good) was observed in 79.3% of patients; SDAI and CDAI remission/low activity was observed in 52.3 and 52.7% of patients, respectively. Some patients achieved clinical response only by the 25th week of treatment. The originally moderate RA activity and administration of methotrexate are the factors determining higher ETN effectivity in RA patients. The general tolerance of ETN was satisfactory; no uncommon adverse effects were observed.
Conclusions. Analysis of the results of ETN therapy for 6 months attests to high effectiveness of this drug. Its advantages include the rapid clinical effect in most patients and good tolerance. ETN can be recommended for treatment of patients with moderate and severe RA when the conventional DMARDs therapy turns out to be insufficiently effective.
About the Authors
Anna Olegovna Pchelintseva
Nasonova Research Institute of
Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
E Yu Panasyuk
Nasonova Research Institute of
Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
O F Ryabitseva
Regional Clinical Hospital №1 of the
Sverdlovsk Region, Yekaterinburg, Russia
Russian Federation
Russian Federation
V I Mazurov
St. Petersburg Medical Academy of
Postgraduate Studies, St. Petersburg, Russia
Russian Federation
Russian Federation
I G Salikhov
Kazan State Medical University
Russian Federation
Russian Federation
A E Sizikov
Institute of Clinical Immunology, Siberian Branch, Russian Academy of Medical
Sciences, Novosibirsk, Russia
Russian Federation
Russian Federation
O N Ivanova
Voronezh Regional Clinical Hospital №1, Voronezh, Russia
Russian Federation
Russian Federation
V N Sorotskaya
Tula Regional Hospital, Tula, Russia
Russian Federation
Russian Federation
O V Semagina
8Kalinin Samara Regional Clinical Hospital,
Samara, Russia
Russian Federation
Russian Federation
I V Vinogradova
Ulyanovsk Regional Clinical Hospital,
Ulyanovsk, Russia
Russian Federation
Russian Federation
A I Kulikov
Rostov State Medical University, Regional Clinical Hospital №2, Rostov-on-Don, Russia
Russian Federation
Russian Federation
L N Denisov
Nasonova Research Institute of
Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Russian Federation
Russian Federation
E L Nasonov
Nasonova Research Institute of
Rheumatology, Russian Academy of Medical Sciences, Moscow, Russia
Review
For citations:
Pchelintseva A.O., Panasyuk E.Yu., Ryabitseva O.F., Mazurov V.I., Salikhov I.G., Sizikov A.E., Ivanova O.N., Sorotskaya V.N., Semagina O.V., Vinogradova I.V., Kulikov A.I., Denisov L.N., Nasonov E.L. EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS (results of the Russian multicenter ETALON study). Rheumatology Science and Practice. 2013;51(6):639-45. (In Russ.) https://doi.org/10.14412/1995-4484-2013-639-45
Views:
1209
Email this article 